GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Ertugliflozin - STEGLATRO oral tablets

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - STEGLATRO oral tablets

Product / population
Adults with type 2 diabetes; not a class-wide CKD or heart-failure regimen.
Renal method
Indexed eGFR, mL/min/1.73 m2
Source revision
Revision not established in selected retrieval
Retrieved
2026-09-10
Local review status
Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Before use: Ertugliflozin - STEGLATRO oral tablets

Do not transfer another SGLT2 product's renal eligibility or withholding interval.

What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - STEGLATRO oral tablets

Open original reference

GlobalRPh-hosted RX List · Adults with type 2 diabetes; not a class-wide CKD or heart-failure regimen.

Renal method: Indexed eGFR, mL/min/1.73 m2
Source date: Revision not established in selected retrieval
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Confirm the exact product, indication, renal measure and full source before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The usual initial dose is 5 mg each morning; 15 mg may be used for additional glycemic control if tolerated.

Assess renal function and correct volume depletion first. The mirror advises withholding at least 4 days before major surgery/prolonged fasting; resume only when stable and eating. Hemodialysis removal was not studied.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

STEGLATRO renal eligibility
eGFR, mL/min/1.73 m2Source-specific dose / instruction
>=45No renal adjustment in the selected source
<45Use not recommended
Read the retained text before reformatting

STEGLATRO renal eligibility

eGFR, mL/min/1.73 m2Source-specific dose / instruction
>=45No renal adjustment in the selected source
<45Use not recommended

The usual initial dose is 5 mg each morning; 15 mg may be used for additional glycemic control if tolerated.

Assess renal function and correct volume depletion first. The mirror advises withholding at least 4 days before major surgery/prolonged fasting; resume only when stable and eating. Hemodialysis removal was not studied.

RDM63-rxlist-ertugliflozin-ae0af782a7-C1 · Source locator: Dosage; temporary interruption for surgery; Renal impairment; Overdose

Source-specific limits

The usual initial dose is 5 mg each morning; 15 mg may be used for additional glycemic control if tolerated.

Assess renal function and correct volume depletion first. The mirror advises withholding at least 4 days before major surgery/prolonged fasting; resume only when stable and eating. Hemodialysis removal was not studied.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/steglatro-drug/
Retrieved
2026-09-10
Renal-function method
Indexed eGFR, mL/min/1.73 m2
Source date/version
Revision not established in selected retrieval
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
d065ff785a5bef272a554d8e73e328799e78ba1513a6d7d3ce477bfb46d7d6be

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ertugliflozin&s1=RDM63-rxlist-ertugliflozin-ae0af782a7&h1=ba518e8907a11429b8e5056539d091f62ac8e44af605dee7ecad5488b5b918ef